Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling

Clinical Pharmacokinetics

Volumn 54, Issue 5, 2015, Pages 493-501

  Li, Haibo ^a,b,c   Shi, Qiang ^b  

^a Nantong Center for Disease Control and Prevention   (China)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c Maternal and Child Health Hospital of Nantong   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ADVERSE EFFECTS; AGE; DOSE RESPONSE; DRUG INTERACTION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; METABOLISM; PROCEDURES; SMOKING; SMOKING CESSATION; STANDARDS; UNITED STATES;

AGE FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG LABELING; HUMANS; PRESCRIPTION DRUGS; SMOKING; SMOKING CESSATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84939958648     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0246-6     Document Type: Review

References (21)

1. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–64.
2. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet. 1999;36(6):425–38.
3. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917–21.
4. Kroon LA. Drug interactions and smoking: raising awareness for acute and critical care providers. Crit Care Nurs Clin N Am. 2006;18(1):53–62, xii.
5. Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J Clin Nurs. 2009;18(11):1533–40.
6. Schein JR. Cigarette smoking and clinically significant drug interactions. Ann Pharmacother. 1995;29(11):1139–48.
7. Miller LG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm. 1990;9(2):125–35.
8. US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2011. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Accessed 15 Sept 2014.
9. US Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling. Draft guidance. 2006. http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0344-gdl0001.pdf. Accessed 15 Sept 2014.
10. US Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. Draft guidance. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 15 Sept 2014.
11. Duke J, Friedlin J, Ryan P. A quantitative analysis of adverse events and “overwarning” in drug labeling. Arch Intern Med. 2011;171(10):944–6.
12. Martin CM, Borgelt L. Black box warnings: what do they mean to pharmacists and patients. Consult Pharm. 2012;27(7):482–92.
13. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16(15–16):697–703.
14. Petros WP, Younis IR, Ford JN, Weed SA. Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy. 2012;32(10):920–31.
15. Villard PH, Herber R, Seree EM, Attolini L, Magdalou J, Lacarelle B. Effect of cigarette smoke on UDP-glucuronosyltransferase activity and cytochrome P450 content in liver, lung and kidney microsomes in mice. Pharmacol Toxicol. 1998;82(2):74–9.
16. Seminerio MJ, Ratain MJ. Are drug labels static or dynamic? Clin Pharmacol Ther. 2013;94(3):302–4.
17. Fang H, Su Z, Wang Y, Miller A, Liu Z, Howard PC, et al. Exploring the FDA Adverse Event Reporting System to generate hypotheses for monitoring of disease characteristics. Clin Pharmacol Ther. 2014;95(5):496–8.
18. Hoffman KB, Demakas AR, Dimbil M, Tatonetti NP, Erdman CB. Stimulated reporting: the impact of US Food and Drug Administration-issued alerts on the Adverse Event Reporting System (FAERS). Drug Saf. 2014;37(11):971–80.
19. Gagne JJ, Bykov K, Choudhry NK, Toomey TJ, Connolly JG, Avorn J. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ. 2013;347:f5307.
20. Zaverucha-do-Valle C, Monteiro SP, El-Jaick KB, Rosadas LA, Costa MJ, Quintana MS, et al. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients. Tuberculosis. 2014;94(3):299–305.
21. Matlock A, Allan N, Wills B, Kang C, Leikin JB. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility. Clin Toxicol. 2011;49(6):443–7.